ANI Pharmaceuticals (NASDAQ:ANIP) Downgraded by StockNews.com to Sell

StockNews.com downgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a hold rating to a sell rating in a research note published on Monday.

ANIP has been the topic of several other research reports. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. HC Wainwright reissued a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday. Finally, Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $77.71.

ANI Pharmaceuticals Stock Performance

ANIP opened at $58.46 on Monday. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of -106.29 and a beta of 0.74. The business’s 50-day moving average price is $57.23 and its two-hundred day moving average price is $58.13. ANI Pharmaceuticals has a 1 year low of $52.50 and a 1 year high of $70.81. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

Insider Transactions at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the sale, the senior vice president now owns 49,059 shares in the company, valued at approximately $2,943,540. This trade represents a 2.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Stephen P. Carey sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the transaction, the chief financial officer now directly owns 154,468 shares in the company, valued at $8,617,769.72. The trade was a 4.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,300 shares of company stock worth $584,009 in the last ninety days. Insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Louisiana State Employees Retirement System grew its stake in ANI Pharmaceuticals by 3.9% during the third quarter. Louisiana State Employees Retirement System now owns 8,000 shares of the specialty pharmaceutical company’s stock worth $477,000 after buying an additional 300 shares in the last quarter. State of Alaska Department of Revenue lifted its holdings in ANI Pharmaceuticals by 5.2% during the 3rd quarter. State of Alaska Department of Revenue now owns 9,467 shares of the specialty pharmaceutical company’s stock worth $564,000 after buying an additional 464 shares during the period. New York State Teachers Retirement System raised its holdings in ANI Pharmaceuticals by 1.7% during the 3rd quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock worth $1,439,000 after purchasing an additional 394 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in ANI Pharmaceuticals by 6.9% in the third quarter. Principal Financial Group Inc. now owns 89,961 shares of the specialty pharmaceutical company’s stock valued at $5,367,000 after buying an additional 5,829 shares during the period. Finally, Summit Global Investments lifted its stake in shares of ANI Pharmaceuticals by 154.2% in the 3rd quarter. Summit Global Investments now owns 19,704 shares of the specialty pharmaceutical company’s stock valued at $1,176,000 after purchasing an additional 11,952 shares during the period. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.